Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2014 Financial Results on July 31, 2014

  Seattle Genetics to Host Conference Call and Webcast Discussion of Second   Quarter 2014 Financial Results on July 31, 2014  Business Wire  BOTHELL, Wash. -- July 9, 2014  Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its second quarter 2014 financial results on Thursday, July 31, 2014, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:  LIVE access on Thursday, July 31, 2014  1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time    *Telephone 800-839-7875 (domestic) or 913-312-0979 (international);     conference ID 7088135   *Webcast available at www.seattlegenetics.com/ in the Investors and News     section  REPLAY access    *Telephone replay will be available beginning at approximately 4:30 p.m. PT     on Thursday, July 31, 2014 through 10:00 p.m. PT on Monday, August 4, 2014     by calling 888-203-1112 (domestic) or 719-457-0820 (international);     conference ID 7088135   *Webcast replay will be available on the Seattle Genetics website at     www.seattlegenetics.com/ in the Investors and News section  About Seattle Genetics  Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. The company’s lead product, ADCETRIS^® (brentuximab vedotin), is an ADC that, in collaboration with Takeda Pharmaceutical Company Limited, is commercially available for two indications in more than 40 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 30 ongoing clinical trials. Seattle Genetics is also advancing a robust pipeline of clinical-stage ADC programs, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, ASG-22ME and ASG-15ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and Pfizer. More information can be found at www.seattlegenetics.com.  Contact:  Seattle Genetics, Inc. Peggy Pinkston, 425-527-4160 ppinkston@seagen.com  
Press spacebar to pause and continue. Press esc to stop.